Last update Nov. 8, 2023

Tirzepatide

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Tirzepatide is a long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a glucagon-like peptide 1 (GLP-1) receptor agonist. It increases insulin sensitivity and secretion, suppresses glucagon secretion, and slows gastric emptying. It is used in the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. It is also used in the treatment of obesity. Weekly subcutaneous administration.

At the time of the last update, we found no published data on its excretion in breast milk.

Its very high molecular weight and high binding to plasma proteins make it very unlikely to pass into breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract and is not absorbed (oral bioavailability is practically nil), which makes it difficult or impossible for it to pass into the infant's plasma from ingested breast milk, except in premature infants and in the immediate neonatal period, where there may be greater intestinal permeability.

Alternatives

  • Glibenclamide (Safe substance and/or breastfeeding is the best option.)
  • Glipizide (Safe substance and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Miglitol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Tirzepatide in other languages or writings:

  • تيرزيباتيد (Arabic)
  • Тирзепатид (Cyrillic)
  • 替尔泊肽 (Chinese)
  • l-tyrosyl-2-methylalanyl-l-α-glutamylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-α-aspartyl-l-tyrosyl-l-seryl-l-isoleucyl-2-methylalanyl-l-leucyl-l-α-aspartyl-l-lysyl-l-isoleucyl-l-alanyl-l-glutaminyl-N 6-[(22S)-22,42-dicarboxy-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazadotetracontan-1-oyl]-l-lysyl-l-alanyl-l-phenylalanyl-l-valyl-l-glutaminyl-l-tryptophyl-l-leucyl-l-isoleucyl-l-alanylglycylglycyl-l-prolyl-l-seryl-l-serylglycyl-l-alanyl-l-prolyl-l-prolyl-l-prolyl-l-serinamide (Chemical name)
  • C225H348N48O68 (Molecular formula)
  • A10BX16 (ATC Code/s)

Group

Tirzepatide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Tirzepatide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 4.814 daltons
Protein Binding 99 %
VD 0.14 l/Kg
Tmax 8 - 72 hours
T½ 120 hours

References

  1. Eli-Lilly. Tirzepatide (Mounjaro). Drug Summary. 2022 Full text (in our servers)

Total visits

2,529

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM